Non-Hodgkin Lymphoma Clinical Trials in Omaha, Nebraska

8 studies are recruiting for non-hodgkin lymphoma in Omaha, Nebraska right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

   This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   35 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT05826535 on ClinicalTrials.gov

2. A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

   This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-targeting CD19/CD20 CAR T-cell therapy, with investigator's choice of CD19 CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma in the second-line setting.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Nebraska Medical Center (UNMC), Omaha, Nebraska

   Locations

   36 in total

   Run by

   Lyell Immunopharma, Inc.

   See if you can join NCT07188558 on ClinicalTrials.gov

3. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

   This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

   Stage

   Not phased

   Ages

   Any age

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Locations

   142 in total

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT01351545 on ClinicalTrials.gov

4. Halt Aging in Survivors of Blood Cancers

   Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting th…

   Stage

   Not phased

   Ages

   50 and older

   Site

   University of Nebraska Medical Center, Omaha, Nebraska

   Run by

   University of Nebraska

   See if you can join NCT07292272 on ClinicalTrials.gov

5. Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

   A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Nebraska Cancer Specialists, Omaha, Nebraska

   Locations

   39 in total

   Run by

   CellCentric Ltd.

   See if you can join NCT04068597 on ClinicalTrials.gov

6. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

   The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University Of Nebraska Medical Center, Omaha, Nebraska

   Locations

   38 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876649 on ClinicalTrials.gov

7. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

   Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   University Of Nebraska Medical Center, Omaha, Nebraska

   Locations

   36 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06876662 on ClinicalTrials.gov

8. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

   International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

   Stage

   Not phased

   Ages

   Any age

   Site

   Massive Bio SYNERGY-AI site, Omaha, Nebraska

   Locations

   68 in total

   Run by

   Massive Bio, Inc.

   See if you can join NCT03452774 on ClinicalTrials.gov